 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (clinicaltrials.gov) - Feb 20, 2014
P3, N=1208, Active, not recruiting, Sponsor: University of Pennsylvania
Completed --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Analysis of Aqueous and Vitreous Humor (clinicaltrials.gov) - Feb 18, 2014
P2, N=45, Not yet recruiting, Sponsor: California Retina Consultants
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=20, Active, not recruiting, Sponsor: Southeast Retina Center, Georgia
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Feb 17, 2014
P3, N=282, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Camellia: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Feb 17, 2014
P3, N=252, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: T-REX: Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (clinicaltrials.gov) - Feb 17, 2014
P3, N=60, Active, not recruiting, Sponsor: Charles C Wykoff, PhD, MD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- PAN-90806 / PanOptica
Enrollment open: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Feb 12, 2014
P1, N=30, Recruiting, Sponsor: PanOptica, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Feb 10, 2014
P4, N=60, Completed, Sponsor: Universit
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: ReCaLL: Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - Feb 9, 2014
P4, N=50, Not yet recruiting, Sponsor: GWT-TUD GmbH
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Feb 3, 2014
P4, N=30, Not yet recruiting, Sponsor: Federal University of S
- ||||| razuprotafib subcutaneous (AKB-9778 SC) / Aadi Biosci, EyePoint Pharma
New P2 trial, Monotherapy: The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jan 29, 2014
P2, N=120, Recruiting, Sponsor: Aerpio Therapeutics
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema (clinicaltrials.gov) - Jan 22, 2014
P=N/A, N=300, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting N=400 --> 300
- |||||||||| Avegra (bevacizumab biosimilar) / Biocad
New P3 trial: GALATIR: Safety and Efficacy Study of BCD-021 Compared to Lucentis (clinicaltrials.gov) - Jan 12, 2014
P3, N=108, Not yet recruiting, Sponsor: Biocad
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Enrollment open: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jan 12, 2014
P3, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
N=400 --> 300 Not yet recruiting --> Recruiting
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Jan 9, 2014
P3, N=150, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Jan 8, 2014
P3, N=28, Completed, Sponsor: Medical University of Vienna
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jan 7, 2014
P3, N=155, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| PF 4634817 / Pfizer
Enrollment open: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema (clinicaltrials.gov) - Jan 7, 2014
P2, N=200, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Liberty: Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jan 6, 2014
P4, N=60, Recruiting, Sponsor: Retinal Consultants of Arizona
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) (clinicaltrials.gov) - Jan 2, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: University of Luebeck
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | PAN-90806 / PanOptica
New P1 trial: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Dec 25, 2013
P1, N=30, Recruiting, Sponsor: PanOptica, Inc.
- ||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Enrollment change: Safety and Efficacy Study of Ozurdex (clinicaltrials.gov) - Dec 15, 2013
P4, N=309, Active, not recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting N=400 --> 309
- ||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Enrollment closed: Safety and Efficacy Study of Ozurdex (clinicaltrials.gov) - Dec 15, 2013
P4, N=309, Active, not recruiting, Sponsor: Allergan
N=400 --> 309 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: REEF: Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab (clinicaltrials.gov) - Dec 9, 2013
P1/2, N=40, Completed, Sponsor: California Retina Consultants
Recruiting --> Active, not recruiting N=30 --> 40
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: REEF: Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab (clinicaltrials.gov) - Dec 9, 2013
P1/2, N=40, Completed, Sponsor: California Retina Consultants
N=30 --> 40 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion (clinicaltrials.gov) - Dec 9, 2013
P1, N=20, Completed, Sponsor: California Retina Consultants
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment closed: Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Dec 8, 2013
P2, N=271, Active, not recruiting, Sponsor: Allergan
Recruiting --> Completed Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab and the Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Dec 8, 2013
P4, N=380, Completed, Sponsor: Ural State Medical Academy
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Monotherapy: PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Dec 5, 2013
P4, N=31, Active, not recruiting, Sponsor: University of Sao Paulo
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SHIFT-2: Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections (clinicaltrials.gov) - Dec 3, 2013
P4, N=200, Recruiting, Sponsor: Michael Brent
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200 (clinicaltrials.gov) - Dec 2, 2013
P4, N=330, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| PF 4634817 / Pfizer
New P2 trial: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema (clinicaltrials.gov) - Nov 21, 2013
P2, N=200, Recruiting, Sponsor: Pfizer
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: BGB/IST: Evaluation of Dosing Interval of Higher Doses of Ranibizumab (clinicaltrials.gov) - Nov 20, 2013
P4, N=37, Completed, Sponsor: Brandon G. Busbee, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: UNRAVEL: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Nov 18, 2013
P4, N=204, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=150, Active, not recruiting, Sponsor: Barnes Retina Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - Nov 17, 2013
P4, N=5000, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks (clinicaltrials.gov) - Nov 4, 2013
P1, N=0, Withdrawn, Sponsor: Montana Compton
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks (clinicaltrials.gov) - Nov 4, 2013
P1, N=0, Withdrawn, Sponsor: Montana Compton
Recruiting --> Withdrawn N=20 --> 0
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: SALT: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (clinicaltrials.gov) - Nov 4, 2013
P4, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 0 Not yet recruiting --> Recruiting
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Nov 3, 2013
P3, N=282, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Camellia: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Nov 3, 2013
P3, N=252, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema (clinicaltrials.gov) - Nov 2, 2013
P3, N=187, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200 (clinicaltrials.gov) - Oct 28, 2013
P4, N=330, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Safety and Efficacy of Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Oct 28, 2013
P1/2, N=30, Not yet recruiting, Sponsor: The Cleveland Clinic
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: RESCUE: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. (clinicaltrials.gov) - Oct 28, 2013
P1/2, N=8, Recruiting, Sponsor: Northern California Retina Vitreous Associates
- || Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: POLARIS: Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=807, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Sep 2012 --> Apr 2013
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: COMRADE-C: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Oct 27, 2013
P3, N=242, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2012 --> Apr 2013 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
New P1 trial: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia (clinicaltrials.gov) - Oct 22, 2013
P1, N=60, Completed, Sponsor: Second University of Naples
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: RabOCT: Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT (clinicaltrials.gov) - Oct 21, 2013
P2, N=24, Recruiting, Sponsor: University of Leipzig